Aiko Umeda

Title: Aiko Umeda: Innovator in Metabolic Disorder Treatments

Introduction

Aiko Umeda is a prominent inventor based in Woodland Hills, CA (US). She has made significant contributions to the field of metabolic disorder treatments. Her innovative approach focuses on utilizing binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists.

Latest Patents

Aiko Umeda holds 1 patent for her groundbreaking work titled "Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists." This patent outlines methods for treating metabolic diseases and disorders, including type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, and diabetic nephropathy. The patent emphasizes the administration of an antigen binding protein in conjunction with a GLP-1 receptor agonist.

Career Highlights

Aiko Umeda is currently associated with Amgen Inc., a leading biotechnology company. Her work at Amgen has been pivotal in advancing therapeutic strategies for metabolic disorders. She has dedicated her career to researching and developing innovative solutions that address critical health challenges.

Collaborations

Aiko has collaborated with notable colleagues, including Darren L Bates and Donghui Shi. These partnerships have fostered a collaborative environment that enhances the development of effective treatments for metabolic conditions.

Conclusion

Aiko Umeda's contributions to the field of metabolic disorder treatments exemplify her commitment to innovation and health improvement. Her patent and work at Amgen Inc. highlight her role as a key player in advancing medical science.